公开(公告)号：US20230295320A1

公开(公告)日：2023-09-21

申请号：US17898384

申请日：2022-08-29

申请人： Ambrx, Inc.

发明人： Richard S Barnett ,  Nickolas Knudsen ,  Ying Sun ,  Sandra Biroc ,  Timothy Buss ,  Tsotne Javahishvili ,  Damien Bresson ,  Shailaja Srinagesh ,  Amha Hewet ,  Jason Pinkstaff

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61K47/42 ,  C07K5/062

CPC分类号： C07K16/2875 ,  A61K47/6889 ,  A61K47/6817 ,  A61K47/6845 ,  A61K47/42 ,  C07K5/06052 ,  C07K2317/76

摘要： This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are aCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the aCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

公开(公告)号：US10800856B2

公开(公告)日：2020-10-13

申请号：US14406190

申请日：2013-06-07

申请人： Ambrx, Inc.

发明人： Richard S. Barnett ,  Feng Tian ,  Anna-Maria A. Hays Putnam ,  Marco Gymnopoulos ,  Nick Knudsen ,  Andrew Beck ,  Ying Sun

IPC分类号： A61K47/68 ,  A61K49/00 ,  C07K16/40 ,  C07K16/30 ,  C07K5/02

摘要： This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

公开(公告)号：US20150080559A1

公开(公告)日：2015-03-19

申请号：US14122667

申请日：2012-05-24

申请人： AMBRX, INC.

发明人： Zhenwei Miao ,  Kyle Atkinson ,  Sandra Biroc ,  Timothy Buss ,  Melissa Neal ,  Vadim Kraynov ,  Robin Mardsen ,  Jason Pinkstaff ,  Lillian Skidmore ,  Ying Sun ,  Agnieszka Szydlik ,  Ianina Valenta

IPC分类号： C07K5/06 ,  C07K16/28 ,  A61K47/48

CPC分类号： C07K5/06 ,  A61K31/337 ,  A61K31/427 ,  A61K39/39558 ,  A61K47/6803 ,  A61K47/6855 ,  A61K2039/505 ,  C07D207/325 ,  C07D401/12 ,  C07D417/12 ,  C07K5/02 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/76 ,  A61K2300/00

摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

摘要翻译： 本文公开了包含至少一种非天然氨基酸的非天然氨基酸和多拉斯达汀类似物，以及用于制备这种非天然氨基酸和多肽的方法。 多拉司他汀类似物可以包括广泛的可能功能，但通常具有至少一个肟，羰基，二羰基和/或羟胺基团。 本文还公开了在翻译后进一步修饰的非天然氨基酸多拉司他汀类似物，用于实现这种修饰的方法，以及纯化这种多拉司他汀类似物的方法。 通常，修饰的多拉司他汀类似物包括至少一个肟，羰基，二羰基和/或羟胺基团。 进一步披露的是使用这种非天然氨基酸多拉司他汀类似物和经修饰的非天然氨基酸多拉司他丁类似物的方法，包括治疗，诊断和其他生物技术用途。

公开(公告)号：US11510993B2

公开(公告)日：2022-11-29

申请号：US15765515

申请日：2016-09-30

申请人： Merck Sharp & Dohme Corp. ,  Ambrx, Inc.

发明人： Philip E. Brandish ,  Robert M. Garbaccio ,  Jeffrey Kern ,  Linda Liang ,  Sanjiv Shah ,  Dennis Zaller ,  Andrew Beck ,  Dennis Gately ,  Nick Knudsen ,  Anthony Manibusan ,  Jianing Wang ,  Ying Sun

IPC分类号： A61K47/68 ,  C07K16/28 ,  A61K45/06

摘要： Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.

公开(公告)号：US11459392B2

公开(公告)日：2022-10-04

申请号：US16224346

申请日：2018-12-18

申请人： Ambrx, Inc.

发明人： Richard S Barnett ,  Nick Knudsen ,  Ying Sun ,  Sandra Biroc ,  Timothy Buss ,  Tsotne Javahishvili ,  Damien Bresson ,  Shailaja Srinagesh ,  Amha Hewet ,  Jason Pinkstaff

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61K47/42 ,  C07K5/062

摘要： This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

公开(公告)号：US11420999B2

公开(公告)日：2022-08-23

申请号：US17142169

申请日：2021-01-05

申请人： Ambrx, Inc.

发明人： Zhenwei Miao ,  Kyle Atkinson ,  Sandra Biroc ,  Timothy Buss ,  Melissa Neal ,  Vadim Kraynov ,  Robin Marsden ,  Jason Pinkstaff ,  Lillian Skidmore ,  Ying Sun ,  Agnieszka Szydlik ,  Delia Ianina Lopez De Valenta

IPC分类号： C07K5/10 ,  C07K5/103 ,  C07D207/08 ,  C07D401/12 ,  C07D417/12 ,  C07K5/02 ,  A61K47/68 ,  A61K38/07 ,  C07K5/062

摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.

公开(公告)号：US20220033518A1

公开(公告)日：2022-02-03

申请号：US17003952

申请日：2020-08-26

申请人： Ambrx,Inc.

发明人： Richard Barnett ,  Feng Tian ,  Anna-Maria A. Hays Putnam ,  Marco Gymnopoulos ,  Nickolas Knudsen ,  Andrew Beck ,  Ying Sun

IPC分类号： C07K16/40 ,  C07K16/30 ,  C07K5/02 ,  A61K47/68

摘要： This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

公开(公告)号：US20180009845A1

公开(公告)日：2018-01-11

申请号：US15702682

申请日：2017-09-12

申请人： Ambrx, Inc.

发明人： Zhenwei Maio ,  Kyle Atkinson ,  Sandra Biroc ,  Timothy Buss ,  Melissa Neal ,  Vadim Kraynov ,  Robin Marsden ,  Jaosn Pinkstaff ,  Lillian Skidmore ,  Ying Sun ,  Agnieszka Szydlik ,  Delia Lanina Lopez De Valenta

IPC分类号： C07K5/103 ,  C07K5/02 ,  C07D401/12 ,  C07D207/08 ,  A61K38/07 ,  C07D417/12 ,  C07K5/062

CPC分类号： C07K5/101 ,  A61K38/07 ,  A61K47/6803 ,  A61K47/6817 ,  A61K47/6849 ,  A61K47/6855 ,  A61K47/6861 ,  C07D207/08 ,  C07D401/12 ,  C07D417/12 ,  C07K5/0205 ,  C07K5/06043

摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.

公开(公告)号：US20150152190A1

公开(公告)日：2015-06-04

申请号：US14406190

申请日：2013-06-07

申请人： Ambrx, Inc.

发明人： Richard S. Barnett ,  Feng Tian ,  Anna-Maria A. Hays Putnam ,  Marco Gymnopoulos ,  Nick Knudsen ,  Andrew Beck ,  Ying Sun

IPC分类号： C07K16/40 ,  C07K7/06

摘要： This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

摘要翻译： 本发明涉及包含至少一种非天然编码氨基酸的前列腺特异性膜抗原（PSMA）抗体和抗体药物偶联物。 本文公开了具有一种或多种非天然编码氨基酸的αPSMA抗体，并且还公开了抗体药物偶联物，其中本发明的αPSMA抗体与一种或多种毒素缀合。 本文还公开了在翻译后进一步修饰的非天然氨基酸多拉司他汀类似物，用于实现这种修饰的方法，以及纯化这种多拉司他汀类似物的方法。 通常，修饰的多拉司他汀类似物包括至少一个肟，羰基，二羰基和/或羟胺基团。 进一步披露的是使用这种非天然氨基酸抗体药物偶联物，多拉司他汀类似物和经修饰的非天然氨基酸多拉司他汀类似物的方法，包括治疗，诊断和其他生物技术用途。

公开(公告)号：US20150152187A1

公开(公告)日：2015-06-04

申请号：US14407792

申请日：2013-06-14

申请人： Ambrx, Inc.

发明人： Ying Sun ,  Ning Zou ,  Amha Hewet ,  Jason K. Pinkstaff ,  Shailaja Srinagesh ,  Richard S. Barnett ,  Feng Tian ,  Anna-Maria A. Hays Putnam ,  Marco Gymnopoulos ,  Nick Knudsen ,  Andrew Beck

IPC分类号： C07K16/30 ,  A61K47/48

CPC分类号： C07K16/3076 ,  A61K47/6869 ,  C07K16/3069

摘要： This invention relates to anti-prostate-specific membrane antigen antibodies (αPSMA) and αPSMA antibody—nuclear receptor ligand (NRL) conjugates comprising at least one non-naturally-encoded amino acid.

摘要翻译： 本发明涉及包含至少一种非天然编码氨基酸的抗前列腺特异性膜抗原抗体（αPSMA）和αPSMA抗体 - 核受体配体（NRL）缀合物。